Document Detail

Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience.
MedLine Citation:
PMID:  22875883     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Inflammation following acute myocardial infarction (MI) has detrimental effects on reperfusion, myocardial remodelling, and ventricular function. Magnetic resonance imaging using ultrasmall superparamagnetic particles of iron oxide can detect cellular inflammation in tissues, and we therefore explored their role in acute MI in humans.
METHODS AND RESULTS: Sixteen patients with acute ST-segment elevation MI were recruited to undergo 3 sequential magnetic resonance scans within 5 days of admission at baseline, 24 and 48 hours following no infusion (controls; n=6) or intravenous infusion of ultrasmall superparamagnetic particles of iron oxide (n=10; 4 mg/kg). T2*-weighted multigradient-echo sequences were acquired and R2* values were calculated for specific regions of interest. In the control group, R2* values remained constant in all tissues across all scans with excellent repeatability (bias of -0.208 s(-1), coefficient of repeatability of 26.96 s(-1); intraclass coefficient 0.989). Consistent with uptake by the reticuloendothelial system, R2* value increased in the liver (84±49.5 to 319±70.0 s(-1); P<0.001) but was unchanged in skeletal muscle (54±8.4 to 67.0±9.5 s(-1); P>0.05) 24 hours after administration of ultrasmall superparamagnetic particles of iron oxide. In the myocardial infarct, R2* value increased from 41.0±12.0 s(-1) (baseline) to 155±45.0 s(-1) (P<0.001) and 124±35.0 s(-1) (P<0.05) at 24 and 48 hours, respectively. A similar but lower magnitude response was seen in the remote myocardium, where it increased from 39±3.2 s(-1) (baseline) to 80±14.9 s(-1) (P<0.001) and 67.0±15.7 s(-1) (P<0.05) at 24 and 48 hours, respectively.
CONCLUSIONS: Following acute MI, uptake of ultrasmall superparamagnetic particles of iron oxide occurs with the infarcted and remote myocardium. This technique holds major promise as a potential method for assessing cellular myocardial inflammation and left ventricular remodelling, which may have a range of applications in patients with MI and other inflammatory cardiac conditions.
Shirjel R Alam; Anoop S V Shah; Jennifer Richards; Ninian N Lang; Gareth Barnes; Nikhil Joshi; Tom MacGillivray; Graham McKillop; Saeed Mirsadraee; John Payne; Keith A A Fox; Peter Henriksen; David E Newby; Scott I K Semple
Related Documents :
21586693 - Intravascular ultrasound findings of early stent thrombosis after primary percutaneous ...
18804743 - Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. the c...
1645073 - Epidemiology of major congenital heart defects in sweden, 1981-1986.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-08-08
Journal Detail:
Title:  Circulation. Cardiovascular imaging     Volume:  5     ISSN:  1942-0080     ISO Abbreviation:  Circ Cardiovasc Imaging     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-19     Completed Date:  2012-11-23     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  101479935     Medline TA:  Circ Cardiovasc Imaging     Country:  United States    
Other Details:
Languages:  eng     Pagination:  559-65     Citation Subset:  IM    
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Angioplasty, Balloon, Coronary / instrumentation
Dextrans / administration & dosage,  diagnostic use*,  pharmacokinetics
Infusions, Intravenous
Magnetic Resonance Imaging*
Magnetite Nanoparticles / administration & dosage,  diagnostic use*
Middle Aged
Myocardial Infarction / complications,  diagnosis*,  metabolism,  pathology,  therapy
Myocarditis / diagnosis*,  etiology,  metabolism,  pathology
Myocardium / metabolism,  pathology*
Pilot Projects
Predictive Value of Tests
Reproducibility of Results
Thrombolytic Therapy
Time Factors
Tissue Distribution
Treatment Outcome
Triiodobenzoic Acids / administration & dosage,  diagnostic use*,  pharmacokinetics
Ventricular Remodeling
Grant Support
FS/09/019/26905//British Heart Foundation; FS/12/83/29781//British Heart Foundation; G0701127//Medical Research Council
Reg. No./Substance:
0/Magnetite Nanoparticles; 0/Triiodobenzoic Acids; 0/ferumoxtran-10; 92339-11-2/iodixanol; K3R6ZDH4DU/Dextrans
Comment In:
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):551-4   [PMID:  22991284 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocy...
Next Document:  Prognostic Value of Right Ventricular Longitudinal Peak Systolic Strain in Patients with Pulmonary H...